We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-3.02%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$34.5B
AUM Growth
-$708M
(-2%)
Cap. Flow
+$1.23B
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
13.77%
Holding
2,852
New
233
Increased
919
Reduced
1,343
Closed
332
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enphase Energy
ENPH
|
+$342M |
| 2 |
Intel
INTC
|
+$276M |
| 3 |
TSMC
TSM
|
+$237M |
| 4 |
Procter & Gamble
PG
|
+$178M |
| 5 |
JPMorgan Chase
JPM
|
+$170M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$383M |
| 2 |
Occidental Petroleum
OXY
|
+$321M |
| 3 |
PayPal
PYPL
|
+$316M |
| 4 |
S&P Global
SPGI
|
+$145M |
| 5 |
Datadog
DDOG
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.57% |
| 2 | Healthcare | 17.95% |
| 3 | Financials | 9.89% |
| 4 | Industrials | 9.61% |
| 5 | Consumer Discretionary | 7.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Neurogene
NGNE
$663M
| $252K | ﹤0.01% |
19,700
+320
| +2% | +$6.53K |
|
|
TECX
2127
Tectonic Therapeutic
TECX
$562M
| $252K | ﹤0.01% |
32,683
-14,650
| -31% | -$163K |
|
|
OPNT
2128
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| $252K | ﹤0.01% |
23,400
-51,000
| -69% | -$578K |
|
2129
XBiotech
XBIT
$69.2M
| $251K | ﹤0.01% |
69,300
+37,500
| +118% | +$177K |
|
|
SLGC
2130
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $251K | ﹤0.01% |
86,700
+70,200
| +425% | +$296K |
|
2131
Biglari Holdings Class B
BH
$1.18B
| $250K | ﹤0.01% |
2,159
-2,200
| -50% | -$276K |
|
|
BFIN
2132
DELISTED
BankFinancial
BFIN
| $249K | ﹤0.01% |
26,285
-5,600
| -18% | -$54.4K |
|
2133
LCNB Corp
LCNB
$299M
| $249K | ﹤0.01% |
15,700
-12,100
| -44% | -$187K |
|
2134
Lineage Cell Therapeutics
LCTX
$267M
| $249K | ﹤0.01% |
220,063
-43,003
| -16% | -$63.1K |
|
2135
Savara
SVRA
$1.09B
| $249K | ﹤0.01% |
160,415
-2,700
| -2% | -$4.35K |
|
|
PRSU
2136
Pursuit Attractions and Hospitality Inc
PRSU
$1.48B
| $249K | ﹤0.01% |
7,900
-400
| -5% | -$14K |
|
2137
Paymentus
PAY
$4.29B
| $248K | ﹤0.01% |
+25,500
| New | +$316K |
|
2138
Alignment Healthcare
ALHC
$3.81B
| $247K | ﹤0.01% |
+20,900
| New | +$305K |
|
2139
HBT Financial
HBT
$1.31B
| $247K | ﹤0.01% |
13,600
-1,300
| -9% | -$23.6K |
|
2140
Mueller Industries
MLI
$14.7B
| $244K | ﹤0.01% |
+16,400
| New | +$255K |
|
|
VNTR
2141
DELISTED
Venator Materials PLC
VNTR
| $243K | ﹤0.01% |
276,200
-59,600
| -18% | -$100K |
|
2142
Patria Investments
PAX
$1.79B
| $241K | ﹤0.01% |
18,500
-400
| -2% | -$5.59K |
|
2143
Pitney Bowes
PBI
$2.41B
| $241K | ﹤0.01% |
103,500
-189,200
| -65% | -$607K |
|
|
SOHU
2144
Sohu.com
SOHU
$346M
| $241K | ﹤0.01% |
15,000
-8,400
| -36% | -$142K |
|
2145
Outlook Therapeutics
OTLK
$169M
| $240K | ﹤0.01% |
9,825
-7,680
| -44% | -$179K |
|
|
PAYA
2146
DELISTED
Paya Holdings Inc. Class A Common Stock
PAYA
| $240K | ﹤0.01% |
39,200
+10,800
| +38% | +$71K |
|
2147
Larimar Therapeutics
LRMR
$398M
| $239K | ﹤0.01% |
+74,724
| New | +$187K |
|
2148
Colliers International
CIGI
$5.31B
| $238K | ﹤0.01% |
2,600
-2,100
| -45% | -$245K |
|
2149
Anterix
ATEX
$1.78B
| $236K | ﹤0.01% |
+6,600
| New | +$274K |
|
|
CVLY
2150
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $236K | ﹤0.01% |
12,500
-1,300
| -9% | -$27.2K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q3 2022 Portfolio in Review
As of Q3 2022, Two Sigma Advisers held 2,852 positions worth $34.5B, down 2% from $35.3B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Two Sigma Advisers deployed $1.23B of net new capital in Q3 2022, opening 233 new positions and adding to 919 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Netflix, an estimated $383M trimmed.
- Two Sigma Advisers's largest Q3 2022 buy was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
- Two Sigma Advisers added most to Enphase Energy in Q3 2022, an estimated $342M increase.
- Two Sigma Advisers's biggest Q3 2022 reduction was Netflix, cutting an estimated $383M.
- Two Sigma Advisers fully exited S&P Global in Q3 2022, selling an estimated $145M.
- Two Sigma Advisers's ten largest holdings make up 14% of its $34.5B portfolio in Q3 2022.
- Two Sigma Advisers opened 233 new positions and closed 332 in Q3 2022.
- Two Sigma Advisers's portfolio value fell 2% quarter-over-quarter to $34.5B.
Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.